FDA Brief

Warning letters Devices

FDA warning letter to

Beta Bionics, Inc.

High riskIssued Jan 28Posted Feb 24Center for Devices and Radiological Health

FDA says Beta Bionics' iLet Bionic Pancreas system had quality-system failures, including ignored complaints of severe hypoglycemia and diabetic ketoacidosis.

What happened

FDA inspected Beta Bionics' Irvine, California site from June 9 to June 26, 2025, and reviewed complaint records from June 2023 through June 2025. Investigators found the company did not open corrective actions for complaints of device malfunctions tied to serious harm, did not investigate hundreds of complaints about leaking insulin cartridges and bent cannulas, and did not feed post-market safety data into its risk analysis. FDA reviewed the company's responses of July 18, August 29, and October 29, 2025 and judged them not adequate.

What FDA found

  1. The company did not properly analyze complaint data or open corrective and preventive actions (CAPA, a formal fix-and-prevent process) for malfunctions linked to diabetic ketoacidosis and severe hypoglycemia, and closed 56 complaints without acting or explaining why.

    21 CFR 820.100(a)
  2. The company's risk analysis for the iLet system was not kept current, leaving out post-market hazards such as failed circuit boards, involuntary meal announcements, and leaking cartridges.

    21 CFR 820.30(g)
  3. The company closed complaints without investigation, including 31 leaking cartridge or connector complaints and 21 bent cannula complaints tied to diabetic ketoacidosis, and did not ask for failed infusion sets to be returned.

    21 CFR 820.198(a)
  4. The company did not properly control nonconforming product: it found 61 of its printed circuit board mainboards failing a test, did not document the supplier investigation, and did not issue a supplier corrective action.

    21 CFR 820.90(a)
  5. FDA states the devices are misbranded because the firm failed or refused to furnish required material or information under the Medical Device Reporting requirements (the rules for telling FDA about device-related deaths and serious injuries).

    21 U.S.C. ยง 352(t)(2)

What FDA wants

FDA tells Beta Bionics to correct the cited violations and says the company's responses so far are not adequate. FDA asks the firm to continue sending updates on its corrective actions, including the new complaint handling system and the retrospective complaint review.

Who should pay attention

  • makers of software-controlled insulin dosing devices
  • companies that buy circuit board assemblies or infusion sets from suppliers
  • quality teams that decide when complaints must be escalated to CAPA

This is a summary. Read the original letter on fda.gov.

Beta Bionics, Inc.'s FDA history

Recalls in the last 12 months

Jun 24 Class II Beta Bionics, Inc.
Device
iLet Bionic Pancreas, REF: BB1001
The reason for the recall is: it was found in version 3.3.6 of the iLet ACE Pump firmware and all previous releases that a screen unlock failure could occur when the user successfully slides the unlock slider on the Lock Screen, no screen transition occurs, and the user remains on the Lock Screen. Because the user cannot exit the Lock Screen, the user is unable to perform a cartridge change or meal announcement. If this occurs and therapy is in progress, therapy will continue normally until the insulin cartridge is depleted. The user will be unable to perform a cartridge change or a meal announcement and will be stuck on the screen until the battery fully drains. This can lead to hyperglycemia.
May 6 Class II Beta Bionics, Inc.
Device
iLet Bionic Pancreas, REF: BB1001
insulin pump software versions 1.4.2, and 1.4.3 issue with Dexcom Continuous Glucose Monitoring (CGM) G7 sensor may result in delayed CGM reading then switch to non-CGM dosing, leading to only basal/requested meal doses provided, no correction doses/insulin reductions/suspensions for high/low glucose unless blood glucose entered for sensor life or replacement. Potential health risks to users include severe hyperglycemia with and without DKA and severe hypoglycemia.
Apr 22 Class II Beta Bionics, Inc.
Device
iLet Ace Pump Kit REF: BB1001 iLet Dosing Decision Software
it was found that in versions 1.3.7, 1.4.2, and 1.4.3, the Lock Screen and Limited Access Passcode Screen on the iLet graphical user interface (GUI) include certain icons displayed in the status bar that are active, thereby allowing the user to bypass those screens when those icons on the status bar are pressed, allowing unauthorized access while the device is in Limited Access Mode. A Health Risk associated with Limited access mode includes severe hypoglycemia due to unauthorized access to the iLet if someone were to make unauthorized meal announcements or stopped insulin delivery.

Full company page

Similar letters to other companies

  1. Conroe Welding Supply, Inc.

    FDA warns Conroe Welding Supply over medical oxygen manufacturing failures, including untested batches and a container with 99% (b)(4).

    High risk
  2. Peter Schiff Enterprises

    FDA warns Peter Schiff Enterprises over unapproved cardiac devices and serious quality system failures.

    High risk
  3. Chirp Innovations, LLC

    FDA warned Chirp Innovations over quality-system gaps, missing adverse-event reporting procedures, and unapproved marketing of its Halo muscle stimulator for menstrual pain.

    High risk
  4. Rohto Pharmaceutical Co., Ltd.

    FDA cites Rohto Vietnam eye-drop plant for falsified sterility records, poor aseptic practices, and unapproved Cooling Eye Drops.

    High risk